Myovant Sciences to Host Third Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on February 11, 2021
29 janv. 2021 08h30 HE
|
Myovant Sciences, Inc.
BASEL, Switzerland, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and...
Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
26 janv. 2021 06h55 HE
|
Myovant Sciences, Inc.
84.8% and 73.3% of women reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain at one year82.8% average reduction from baseline on the Numerical...
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
20 janv. 2021 08h30 HE
|
Myovant Sciences, Inc.
BASEL, Switzerland, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity...
CORRECTION -- Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
05 janv. 2021 14h57 HE
|
Myovant Sciences, Inc.
BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Myovant Sciences (NYSE: MYOV), please note that in the first paragraph of the...
Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
05 janv. 2021 08h30 HE
|
Myovant Sciences, Inc.
BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, chief...
Myovant Sciences Announces U.S. Availability of ORGOVYX™ for the Treatment of Advanced Prostate Cancer
05 janv. 2021 06h58 HE
|
Myovant Sciences, Inc.
BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that ORGOVYX™ (relugolix),...
Myovant Sciences Appoints Industry Veteran David Marek as Chief Executive Officer
04 janv. 2021 06h58 HE
|
Myovant Sciences, Inc.
BASEL, Switzerland, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of David...
Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
28 déc. 2020 06h30 HE
|
Myovant Sciences, Inc.
Myovant and Pfizer to jointly develop and commercialize ORGOVYX™ (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and CanadaMyovant to receive an upfront payment...
Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
18 déc. 2020 16h49 HE
|
Myovant Sciences, Inc.
ORGOVYX demonstrated a 96.7% response rate in testosterone suppression to castrate levels (< 50 ng/dL) through 48 weeks in the Phase 3 HERO studyConference call and webcast to be held on December...
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
16 déc. 2020 08h30 HE
|
Myovant Sciences, Inc.
BASEL, Switzerland, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity...